accountLONDON (Reuters) - European Union regulators have recommended Pfizer's new genetically targeted lung cancer drug Xalkori for approval, following marketing approval for the medicine in the United States last August. The U.S. drugmaker said on F...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Pfizer wins EU backing for new lung cancer drug
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account